Clinical Trial Update: First-in-Human PfSPZ-LARC2 Vaccination/CHMI [Phase 1]

View source ↗

Summary

First-in-human Phase 1 trial update for the PfSPZ-LARC2 malaria vaccine (CHMI), sponsored by NIAID, currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• PfSPZ-LARC2

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Malaria | Phase 1 | Status: ACTIVE_NOT_RECRUITING